Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFWOTCMKTS:FFNTFNASDAQ:LBPSWOTCMKTS:OASMY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNFW180 Life Sciences$0.01$0.01$0.00▼$0.04N/AN/A98,433 shs51,046 shsFFNTF4Front Ventures$0.00$0.00$0.00▼$0.11N/AN/A1.37 million shs1.53 million shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AOASMYOasmia Pharmaceutical$0.02$0.02$0.01▼$0.05N/A27.8645 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNFW180 Life Sciences0.00%-4.55%+6.33%+10.53%-7.69%FFNTF4Front Ventures0.00%-60.00%-71.43%-98.53%-99.79%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%OASMYOasmia Pharmaceutical0.00%0.00%0.00%0.00%-59.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/AOASMYOasmia PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNFW180 Life Sciences 0.00N/AN/AN/AFFNTF4Front Ventures 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/AOASMYOasmia Pharmaceutical 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/AOASMYOasmia Pharmaceutical$100KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/AOASMYOasmia Pharmaceutical-$35.35MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNFW180 Life SciencesN/AN/AN/AN/AN/AFFNTF4Front VenturesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AOASMYOasmia PharmaceuticalN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/AOASMYOasmia PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipATNFW180 Life SciencesN/AFFNTF4Front VenturesN/ALBPSW4D pharmaN/AOASMYOasmia PharmaceuticalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNFW180 Life Sciences7N/AN/ANot OptionableFFNTF4Front Ventures460N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableOASMYOasmia Pharmaceutical20N/AN/ANot OptionableOASMY, ATNFW, LBPSW, and FFNTF HeadlinesRecent News About These CompaniesVivesto AB Reports Strategic Progress in Q1 2025May 9, 2025 | tipranks.comVivesto AB DRC (OASMY)October 19, 2024 | investing.comAstellas takes $170m charge as it drops DMD gene therapiesSeptember 5, 2024 | pharmaphorum.comPVivesto AB ADR OASMYJanuary 20, 2024 | morningstar.comMVivesto AB (VIVE) NPVOctober 13, 2023 | hl.co.ukVivesto AB (OASMY) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | finance.yahoo.comOMX Stockholm Pharmaceuticals and Biotechnology GI (SX201030GI)July 19, 2023 | investing.comOMX Stockholm Health Care GI (SX20GI)June 4, 2023 | investing.comGlobal Pet Cancer Therapeutics Market Report to 2027 - Featuring Zoetis, AB Science, Karyopharm Therapeutics, Vivesto and Merial Among OthersFebruary 26, 2023 | benzinga.comOasmia Pharmaceutical AB ADR (OASMY)January 11, 2022 | nasdaq.comMedia Sentiment Over TimeOASMY, ATNFW, LBPSW, and FFNTF Company Descriptions180 Life Sciences NASDAQ:ATNFW$0.0084 0.00 (0.00%) As of 06/26/2025 03:33 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4Front Ventures OTCMKTS:FFNTF$0.0002 0.00 (0.00%) As of 06/26/2025 03:11 PM Eastern4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates through THC Cannabis and CBD Wellness segments. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. The CBD Wellness segment sells non-THC hemp derived products. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Oasmia Pharmaceutical OTCMKTS:OASMY$0.02 0.00 (0.00%) As of 06/25/2025Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
